Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMGN $7.63 1.4300 +23.06%
CBMG $16.98 1.1600 +7.33%
CNDO $2.50 0.1500 +6.38%
ARGS $8.32 0.3400 +4.26%
STML $15.48 0.4900 +3.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

EPZM $19.14 -1.4000 -6.82%
GALT $3.22 -0.2300 -6.67%
SRNE $10.09 -0.6900 -6.40%
TGTX $14.24 -0.9100 -6.01%
VSTM $7.30 -0.4100 -5.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Novartis Sees Price War With Amgen, Lilly for Psoriasis Drugs

(Bloomberg) Jan 27, 2015 - Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of an anticipated price war with Amgen Inc. and Eli Lilly & Co. in the U.S., as payers of prescription bills play the drugmakers off of each other.
read article 

Industry Group to Back Results-Focused Care

(New York Times) Jan 28, 2015 - The new coalition said it is committed to finding a way to change financial incentives, moving the bulk of payments to so-called “value-based” arrangements by 2020.
read article 

Obama's 'Precision Medicine' Plan to Boost Research, But Faces Hurdles

(Reuters) Jan 28, 2015 - President Barack Obama's plan to put the United States at the forefront of individually tailored medical treatment should give a much-needed boost to research in the field but experts say it won't work without reforms to healthcare, including drug testing and insurance
read article 

How Do Medical Journalists Approach Cancer Reporting?

( Jan 27, 2015 - Journalists reported that they did not find pharmaceutical press releases to be helpful, preferring direct contact with physicians as their most reliable and prized sources of information.
read article 

Raleigh Drug Co. to Relaunch Cancer Pain Medication; Shares Bounce

(Triangle Business Journal) Jan 27, 2015 - BioDelivery will re-launch breakthrough cancer pain medicine Onsolis in the United States and find a new partner for the drug, ideally returning more revenue.
read article 

Study Highlights Effectiveness of ASCO’s Interoperability Standard

(ASCO in Action) Jan 27, 2015 - ASCO’s oncology-specific interoperability standard for the communication and coordination of care throughout the cancer journey recently demonstrated its effectiveness in two trial implementations.
read article 

January 28, 2015: E&C Chairman Upton Releases Draft of 21st Century Cures Bill

(COA) Jan 28, 2015 - The 21st Century Cures initiative, legislation "to take a comprehensive look at what steps we can take to accelerate the pace of cures in America” has moved from the concept phase to draft bill language.
read article 

RainTree Oncology, Cardinal Health Specialty Solutions Sign Specialty Distribution and GPO Agreement

(Cardinal Health) Jan 27, 2015 – Cardinal Health Specialty Solutions today announced that it has signed a three-year agreement with RainTree Oncology Services to serve as its exclusive distributor for injectable, infused, oral oncolytic and supportive care specialty medications; and for Cardinal Health’s VitalSourceTM to serve as its group purchasing organization (GPO) for injectable and infused medications.
read corporate press release 

Bill Requiring Cost Parity for Cancer Treatments Takes First Step Forward in PA House

( Jan 28, 2015 - The state House Health Committee voted 23-0 to send to the floor a bill that would bar insurers from allowing patients to be charged more for pill-based cancer treatments than traditional chemotherapy.
read article 

Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy

(TheStreet) Jan 27, 2015 - Advaxis stopped using The Dream Team Group in November 2013, so tying responsibility for the company's quadrupled stock price over the past two months to the work of the notorious stock-promotions firm -- as Seeking Alpha's Richard Pearson did last week -- misses the mark.
read article 

EU Clears Novartis to Buy GSK's Oncology Business with Conditions

(Reuters) Jan 28, 2015 - The European Commission said on Wednesday it had cleared the acquisition by Novartis of GSK oncology business subject to conditions.
read article 

Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria

(Yahoo! Finance) Jan 28, 2015 - Advaxis, Inc. announced an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology.
read article 

How, and Why, Chemists Figured Out How to Unboil an Egg

(Washington Post/Speaking of Science) Jan 28, 2015 - The eggs were used as a proxy for a much more serious endeavor: making cancer research more time and cost efficient.
read article (free registration required) 

Cell Mechanism Discovered That May Cause Pancreatic Cancer

(HCI) Jan 27, 2015 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have found that defects in how cells are squeezed out of overcrowded tissue to die, a process called extrusion, may be a mechanism by which pancreatic cancer begins.
read press release 

Novel Radioguided Brain Surgery Technique Could Help Pinpoint Cancerous Tissue

(SNMMI) Jan 27, 2015 — A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons.
read press release 

Drug Combo Suppresses Growth of Late-stage Prostate Cancer Tumors

(Purdue) Jan 27, 2015 - Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds.
read press release 

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

(OSUCCC - James) Jan 26, 2015 - The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study.
read press release 

Prostate Cancer Patients Who Smoke Fare Worse, Study Finds

(U.S. News & World Report/HealthDay News) Jan 27, 2015 - Smoking doubles the chances that a prostate cancer patient will see his disease spread and that he will eventually die from his illness, a new study finds.
read article 

Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

(MarketWatch) Jan 27, 2015 - Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis® (carfilzomib) for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
read article 

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing

(New York Times) Jan 27, 2015 - Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cancer, ending a dispute that was the subject of a landmark Supreme Court ruling that human genes cannot be patented.
read article 

Novartis Pharma Boss Expects Pressure on Cancer Drug Prices

(Reuters) Jan 27, 2015 - Payers are likely to put pressure on drugmakers to lower the cost of cancer medicines, particularly when alternative treatments are available, the head of Novartis' pharma division said on Tuesday.
read article 

Bayer Launches Major New Stroke Trial

(Pharmafile [UK]) Jan 27, 2015 - Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent strokes from recurring
read article 

Prices for Prescription Medicines Rose How Much Last Year?

(Wall Street Journal/Pharmalot blog) Jan 26, 2015 - The prices of prescription medicines is a front-and-center issue as the cost to treat everything from some of the rarest diseases to the most common afflictions is causing increasing concern among payers, physicians and consumers.
read article 

Can This Treatment Help Me? There’s a Statistic for That

(New York Times/The Upshot) Jan 26, 2015 - Developed in the 1980s, the number needed to treat, or N.N.T., tells us how many people must be treated for one person to derive benefit.
read article 

FDA Approves Teva's Generic Version of AstraZeneca's Nexium

(Reuters) Jan 26, 2015 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.
read article